keyword
MENU ▼
Read by QxMD icon Read
search

Acromegaly

keyword
https://www.readbyqxmd.com/read/28214144/ultrasound-and-radiographic-abnormalities-in-a-patient-with-chronic-severe-acromegaly
#1
Rita Fonseca, Alberto Fernández-Martínez, Roberto Miguélez, Jacqueline Uson
No abstract text is available yet for this article.
February 14, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28210908/updates-in-outcomes-of-stereotactic-radiation-therapy-in-acromegaly
#2
REVIEW
Monica Livia Gheorghiu
Purpose Treatment of acromegaly has undergone important progress in the last 20 years mainly due to the development of new medical options and advances in surgical techniques. Pituitary surgery is usually first-line therapy, and medical treatment is indicated for persistent disease, while radiation (RT) is often used as third-line therapy. The benefits of RT (tumor volume control and decreased hormonal secretion) are hampered by the long latency of the effect and the high risk of adverse effects. Stereotactic RT methods have been developed with the aim to provide more precise targeting of the tumor with better control of the radiation dose received by the adjacent brain structures...
February 16, 2017: Pituitary
https://www.readbyqxmd.com/read/28203372/diagnostic-challenges-and-management-of-a-patient-with-acromegaly-due-to-ectopic-growth-hormone-releasing-hormone-secretion-from-a-bronchial-carcinoid-tumour
#3
Nikolaos Kyriakakis, Jacqueline Trouillas, Mary N Dang, Julie Lynch, Paul Belchetz, Márta Korbonits, Robert D Murray
: A male patient presented at the age of 30 with classic clinical features of acromegaly and was found to have elevated growth hormone levels, not suppressing during an oral glucose tolerance test. His acromegaly was originally considered to be of pituitary origin, based on a CT scan, which was interpreted as showing a pituitary macroadenoma. Despite two trans-sphenoidal surgeries, cranial radiotherapy and periods of treatment with bromocriptine and octreotide, his acromegaly remained active clinically and biochemically...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28197813/t2-weighted-mri-signal-intensity-as-a-predictor-of-hormonal-and-tumoral-responses-to-somatostatin-receptor-ligands-in-acromegaly-a-perspective
#4
REVIEW
Iulia Potorac, Albert Beckers, Jean-François Bonneville
T2-weighted MRI signal intensity of GH-secreting pituitary adenomas is gaining recognition as a marker of disease characteristics and may be a predictor of response to treatment of acromegaly. Adenomas that are T2-hypointense are more common, are smaller and are less likely to invade the cavernous sinus compared to the T2-iso and hyperintense tumors. T2-hypointense tumors are also accompanied by higher IGF1 values at baseline. When presurgical somatostatin receptor ligand (SRL) therapy is administered, T2-hypointense adenomas have better hormonal responses and have greater tumor shrinkage...
February 14, 2017: Pituitary
https://www.readbyqxmd.com/read/28179449/the-gip-gipr-axis-is-functionally-linked-to-gh-secretion-increase-in-a-significant-proportion-of-gsp-somatotropinomas
#5
Daniela Regazzo, Marco Losa, Nora Albiger, Maria Rosa Terreni, Giovanni Vazza, Filippo Ceccato, Enzo Emanuelli, Luca Denaro, Carla Scaroni, Gianluca Occhi
Objective: Glucose-dependent insulinotropic polypeptide receptor (GIPR) overexpression has been recently described in a proportion of gsp(-) somatotropinomas and suggested to be associated with the paradoxical increase of GH (GH-PI) during an oral glucose load. Design and Methods: This study was aimed at linking the GIP/GIPR pathway to GH secretion in 25 somatotropinomas-derived primary cultures and correlating molecular with clinical features in acromegalic patients. Given the impairment of the GIPR/GIPR axis in acromegaly, an additional aim was to assess the effect of GH/IGF-1 stimulation on GIP expression in the enteroendocrine cell line STC-1...
February 8, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28176221/pegvisomant-in-acromegaly-an-update
#6
REVIEW
A Giustina, G Arnaldi, F Bogazzi, S Cannavò, A Colao, L De Marinis, E De Menis, E Degli Uberti, F Giorgino, S Grottoli, A G Lania, P Maffei, R Pivonello, E Ghigo
BACKGROUND: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety. AIM: We here reviewed the emerging aspects of the use of PEG in clinical practice in the light of the most recent literature. RESULTS: The clinical use of PEG is still suboptimal, considering that it remains the most powerful tool to control IGF-I in acromegaly allowing to obtain, with a pharmacological treatment, the most important clinical effects in terms of signs and symptoms, quality of life and comorbidities...
February 7, 2017: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/28176162/somatostatin-receptor-ligands-in-the-treatment-of-acromegaly
#7
REVIEW
Monica R Gadelha, Luiz Eduardo Wildemberg, Marcello D Bronstein, Federico Gatto, Diego Ferone
First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical treatment of acromegaly, however the percentage of patients controlled with these drugs significantly varies in the different studies. Many factors are involved in the resistance to SRL. In this review, we update the physiology of somatostatin and its receptors (sst), the use of SRL in the treatment of acromegaly and the factors involved in the response to these drugs. The SRL act through interaction with the sst, which up to now have been characterized as five subtypes...
February 7, 2017: Pituitary
https://www.readbyqxmd.com/read/28168377/biochemical-investigations-in-diagnosis-and-follow-up-of-acromegaly
#8
REVIEW
Katharina Schilbach, Christian J Strasburger, Martin Bidlingmaier
Measurements of human growth hormone (GH) and insulin-like growth-factor I (IGF-I) are cornerstones in the diagnosis of acromegaly. Both hormones are also used as biochemical markers in the evaluation of disease activity during treatment. Management of acromegaly is particularly challenging in cases where discordant information is obtained from measurement of GH concentrations following oral glucose load and from measurement of IGF-I. While in some patients biological factors can explain the discrepancy, in many cases issues with the analytical methods seem to be responsible...
February 6, 2017: Pituitary
https://www.readbyqxmd.com/read/28166592/renin-angiotensin-system-blockade-improves-cardiac-indices-in-acromegaly-patients
#9
Julia D J Thomas, Abhishek Dattani, Filip Zemrak, Thomas Burchell, Scott A Akker, Felicity J L Kaplan, Bernard Khoo, Simon Aylwin, Ashley B Grossman, L Ceri Davies, Márta Korbonits
Blockade of the angiotensin-renin system, with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), has been shown to improve cardiac outcomes following myocardial infarction and delay progression of heart failure. Acromegaly is associated with a disease-specific cardiomyopathy, the pathogenesis of which is poorly understood.The cardiac indices of patients with active acromegaly with no hypertension (Group A, n=4), established hypertension not taking ACEi/ARBs (Group B, n=4) and established hypertension taking ACEi/ARBs (Group C, n=4) were compared using cardiac magnetic imaging...
February 6, 2017: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/28164675/assessment-of-mean-platelet-volume-and-its-effect-on-disease-control-in-patients-with-acromegaly
#10
Dilek Arpaci, Fatih Kuzu, Mustafa Unal, Sevil U Ilikhan, Mustafa C Buyukuysal, Taner Bayraktaroglu
BACKGROUND: Morbidity and mortality rates due to cardiovascular diseases are more common in acromegalic patients than the healthy population. Platelets play a significant role in both the onset and progression of clotting which then cause the development of atherosclerotic plaques. Increased mean platelet volume (MPV) is an indicator of platelet activation and known as an independent risk factor for atherosclerotic processes. The aim of this study was to compare MPV levels between acromegalic and non-acromegalic patients...
November 1, 2016: Clinical Laboratory
https://www.readbyqxmd.com/read/28161730/the-genetic-background-of-acromegaly
#11
REVIEW
Mônica R Gadelha, Leandro Kasuki, Márta Korbonits
Acromegaly is caused by a somatotropinoma in the vast majority of the cases. These are monoclonal tumors that can occur sporadically or rarely in a familial setting. In the last few years, novel familial syndromes have been described and recent studies explored the landscape of somatic mutations in sporadic somatotropinomas. This short review concentrates on the current knowledge of the genetic basis of both familial and sporadic acromegaly.
February 4, 2017: Pituitary
https://www.readbyqxmd.com/read/28156155/assessment-of-diastolic-dysfunction-arterial-stiffness-and-carotid-intima-media-thickness-in-patients-with-acromegaly
#12
Güven Barış Cansu, Nusret Yılmaz, Atakan Yanıkoğlu, Sebahat Özdem, Aytül Belgi Yıldırım, Gültekin Süleymanlar, Hasan Ali Altunbaş
OBJECTIVE: Early diagnosis and treatment of cardiovascular diseases, the most frequent cause of morbidity and mortality in acromegaly, may be an efficient approach to extending the lifespan of the affected patients. Therefore, it is crucial to determine any cardiovascular diseases in the subclinical period. The study objectives were to determine markers of subclinical atherosclerosis and asses heart structure and functioning. METHODS: This was a cross-sectional single-center study in 53 patients with acromegaly and 22 age- and sex-matched healthy individuals...
February 3, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28155173/impact-of-acromegaly-treatment-on-cardiovascular-complications
#13
EDITORIAL
Adriana G Ioachimescu
No abstract text is available yet for this article.
February 3, 2017: Endocrine
https://www.readbyqxmd.com/read/28155171/understanding-and-predicting-fracture-risk-in-acromegaly
#14
EDITORIAL
Natasha M Appelman-Dijkstra, Nienke R Biermasz
No abstract text is available yet for this article.
February 2, 2017: Endocrine
https://www.readbyqxmd.com/read/28150161/diabetes-in-patients-with-acromegaly
#15
REVIEW
A M Hannon, C J Thompson, M Sherlock
Acromegaly is a clinical syndrome which results from growth hormone excess. Uncontrolled acromegaly is associated with cardiovascular mortality, due to an excess of risk factors including diabetes mellitus, hypertension and cardiomegaly. Diabetes mellitus is a frequent complication of acromegaly with a prevalence of 12-37%. This review will provide an overview of a number of aspects of diabetes mellitus and glucose intolerance in acromegaly including the following: 1. Epidemiology and pathophysiology of abnormalities of glucose homeostasis 2...
February 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28127733/the-evaluation-of-central-corneal-thickness-and-intraocular-pressure-in-conjunction-with-tear-igf-1-levels-in-patients-with-acromegaly
#16
Emrah Kan, Elif K Kan, Ali Okuyucu
PURPOSE: To compare the central corneal thickness (CCT), intraocular pressure (IOP), and tear insulin-like growth factor 1 (IGF-1) levels between patients with acromegaly and a control group and to evaluate the possible effect of tear IGF-1 and duration of the disease on CCT and IOP. METHODS: We included 31 patients with acromegaly (study group) and 40 age- and sex-matched controls in the study. Patients with acromegaly were divided into 2 subgroups based on disease status (active/inactive)...
January 27, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28122798/pituitary-acromegaly-not-one-disease
#17
Sylvia L Asa, Walter Kucharczyk, Shereen Ezzat
Acromegaly has traditionally been regarded as a monomorphous disorder resulting from a benign pituitary adenoma. Increasing evidence, however, is highlighting that this disorder is associated with a spectrum of morphologically distinct pituitary tumors with variable clinical, biochemical and radiologic features and differing therapeutic outcomes that are attributed to different genetic and epigenetic changes. These data underscore the need for developing a more refined clinicopathological risk stratification system and implementing personalized targeted therapeutic approaches...
January 25, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28119176/feline-hypersomatotropism-and-acromegaly-tumorigenesis-a-potential-role-for-the-aip-gene
#18
C J Scudder, S J Niessen, B Catchpole, R C Fowkes, D B Church, Y Forcada
Acromegaly in humans is usually sporadic, however up to 20% of familial isolated pituitary adenomas are caused by germline sequence variants of the aryl-hydrocarbon-receptor interacting protein (AIP) gene. Feline acromegaly has similarities to human acromegalic families with AIP mutations. The aim of this study was to sequence the feline AIP gene, identify sequence variants and compare the AIP gene sequence between feline acromegalic and control cats, and in acromegalic siblings. The feline AIP gene was amplified through PCR using whole blood genomic DNA from 10 acromegalic and 10 control cats, and 3 sibling pairs affected by acromegaly...
December 8, 2016: Domestic Animal Endocrinology
https://www.readbyqxmd.com/read/28110235/relationship-between-expression-of-vascular-endothelial-growth-factor-and-the-proliferation-of-prolactinomas
#19
Nan Li Ya, ZhiQuan Jiang
OBJECTIVE: Prolactinomas are the most common functional hormone-producing pituitary lesions, accounting for 30-40% of all pituitary tumors, while in autopsy series their incidence reaches 50%. However, patients with prolactinoma had a higher recurrence percentage and rate than patients with acromegaly or Cushing's disease. Furthermore, prolactinomas have the highest rate of recurrence post-surgery as compared with other pituitary adenomas. At present, this behavior of prolactinoma is largely unexplained, but may be related to definition of cure, or to more frequent microscopic tumor infiltration into normal pituitary tissue, which is not removed at surgery...
February 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/28100630/a-multivariable-prediction-model-for-pegvisomant-dosing-monotherapy-and-in-combination-with-long-acting-somatostatin-analogues
#20
S E Franck, T I M Korevaar, P Petrossians, A F Daly, P Chanson, M L Jaffrain-Réa, T Brue, G K Stalla, D Carvalho, A Colao, V Hána, B Delemer, C Fajardo, A J van der Lely, A Beckers, S J C M M Neggers
BACKGROUND: Effective treatment of acromegaly with pegvisomant (PEGV), a growth hormone receptor antagonist, requires an appropriate dose titration. PEGV doses vary widely among individual patients, and various covariates may affect its dosing and pharmacokinetics. OBJECTIVE: To identify predictors of the PEGV dose required to normalize insulin-like growth factor I (IGF-I) levels during PEGV monotherapy and in combination with long-acting somatostatin analogues (LA-SSAs)...
April 2017: European Journal of Endocrinology
keyword
keyword
12770
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"